Trial Profile
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Bemcentinib (Primary) ; Docetaxel; Granulocyte colony-stimulating factor modulators
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 22 Aug 2023 According to a BerGenBio media release, data from this study was published in the August 2023 issue of Lung Cancer.
- 28 Jun 2022 Planned End Date changed from 1 May 2022 to 1 May 2027.